サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1427861

インフルエンザワクチンの世界市場レポート2024

Influenza Vaccines Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
インフルエンザワクチンの世界市場レポート2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

インフルエンザワクチンの市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には8.0%の年間複合成長率（CAGR）で101億米ドルに成長すると予想されます。予測期間で予想される成長は、気候と環境への配慮、ヘルスケアへのアクセスの改善、新型インフルエンザ株の出現、アジュバントと送達システムの革新、ヘルスケア支出の全体的な増加などの要因に起因すると考えられます。予測期間中に予想される主な動向としては、mRNAワクチン技術の広範な利用、小児予防接種への重点化、季節性インフルエンザ対策の実施、発展途上国におけるワクチン接種率の強化、個別化されたワクチン接種戦略の採用などが挙げられます。

季節性インフルエンザの発生増加により、インフルエンザワクチン市場は成長すると予想されています。季節性インフルエンザは、インフルエンザウイルスによって引き起こされる呼吸器疾患で、特定の期間、通常は寒い季節に循環して感染を引き起こす傾向があります。この傾向は、抗原ドリフト、人口の感受性、環境条件、不完全なワクチン接種率、ユニバーサルワクチン接種の不在などの要因に影響されます。 インフルエンザワクチンは、流行しているウイルス株に対する予防接種を提供することで、季節性インフルエンザの発生率を減らす上で重要な役割を果たします。たとえば、中央医薬品標準管理機構の2022年10月の報告書によると、2021年から2022年のインフルエンザによる推定負担数には、900万人のインフルエンザ罹患、10万人のインフルエンザ関連入院、400万人のインフルエンザ関連の医療機関受診、5,000人のインフルエンザ死亡が含まれています。したがって、季節性インフルエンザの発生の増加がインフルエンザワクチン市場の成長を牽引しています。

インフルエンザワクチン市場の成長は、高齢化人口の増加によってさらに促進されることが予想されます。この人口統計傾向は、社会における高齢者の割合の増加を指しており、この人口セグメントはインフルエンザワクチンを利用して、インフルエンザ感染に関連する重篤な合併症や死亡率の上昇を緩和します。老化プロセスは免疫システムの弱体化につながり、インフルエンザなどの感染症にかかりやすくなる可能性があります。 2022年10月の世界保健機関（WHO）によると、世界の60歳以上の人口は2050年までに倍増し、21億人に達すると予測されています。したがって、高齢化人口の拡大はインフルエンザワクチン市場の重要な推進力です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のインフルエンザワクチン市場、ワクチンタイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 無効化されました
  • ライブ減衰
  • 世界のインフルエンザワクチン市場、価数別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 4価
  • 3価
  • 世界のインフルエンザワクチン市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 注射
  • 点鼻
  • 世界のインフルエンザワクチン市場、年齢層別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 小児
  • 成人
  • 世界のインフルエンザワクチン市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院と薬局
  • 政府および機関の供給
  • その他の流通チャネル

第7章 地域および国の分析

  • 世界のインフルエンザワクチン市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のインフルエンザワクチン市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • インフルエンザワクチン市場の競合情勢
  • インフルエンザワクチン市場企業プロファイル
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • Merck &Co. Inc.
    • Novartis AG
    • Sanofi-Aventis LLC.

第31章 その他の大手および革新的な企業

  • AstraZeneca PLC
  • GlaxoSmithKline plc.
  • Serum Institute of India Private Limited
  • Takeda Pharmaceutical Company Limited
  • Moderna Inc.
  • Viatris Inc.
  • CSL Limited
  • Seqirus Inc.
  • Daiichi Sankyo Company Limited
  • China National Pharmaceutical Group Corporation
  • Shanghai Fosun Pharmaceutical Group Co. Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Shionogi &Co. Ltd.
  • Liaoning Cheng Da Biotechnology Co. Ltd.
  • Novavax AB

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13705

Influenza vaccines, commonly known as flu vaccines, are designed to confer immunity against influenza viruses. These vaccines are quadrivalent, meaning they are formulated to provide protection against four different flu viruses, encompassing two influenza A viruses and two influenza B viruses.

The primary types of influenza vaccines are inactivated and live attenuated vaccines. Inactivated vaccines contain killed or inactivated microorganisms or viruses, stimulating an immune response without causing the disease. They are used to prevent infection and reduce the severity of illness caused by influenza viruses. Inactivated vaccines are available in both quadrivalent and trivalent formulations and are administered through injections and nasal sprays. These vaccines are suitable for both pediatric and adult populations and are distributed through various channels, including hospitals and pharmacies, government and institutional supply, and other distribution networks.

The influenza vaccines market research report is one of a series of new reports from The Business Research Company that provides influenza vaccines market statistics, including influenza vaccines industry global market size, regional shares, competitors with an influenza vaccines market share, detailed influenza vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the influenza vaccines industry. This influenza vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The influenza vaccines market size has grown strongly in recent years. It will grow from $6.91 billion in 2023 to $7.44 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth observed in the historical period can be attributed to factors such as pandemic preparedness, public health initiatives, studies on vaccine effectiveness, recommendations from healthcare professionals, and global influenza surveillance efforts.

The influenza vaccines market size is expected to see strong growth in the next few years. It will grow to $10.1 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The anticipated growth in the forecast period can be attributed to factors such as climate and environmental considerations, improvements in healthcare accessibility, the emergence of new influenza strains, innovations in adjuvants and delivery systems, and the overall increase in healthcare expenditure. Major trends expected in the forecast period include the wider use of mRNA vaccine technology, a focus on pediatric immunization, implementation of seasonal influenza control measures, enhanced vaccination coverage in developing nations, and the adoption of tailored vaccination strategies.

The influenza vaccine market is anticipated to witness growth due to the increasing occurrences of seasonal influenza. Seasonal influenza, a respiratory illness caused by influenza viruses, tends to circulate and cause infections during specific periods, typically in colder months. This trend is influenced by factors such as antigenic drift, population susceptibility, environmental conditions, incomplete vaccine coverage, and the absence of universal vaccination. Influenza vaccines play a crucial role in reducing the incidence of seasonal influenza by providing immunization against circulating virus strains. For instance, as per the Central Drugs Standard Control Organization's October 2022 report, the estimated burden of influenza for 2021-2022 included nine million flu illnesses, 100,000 flu-related hospitalizations, 4 million flu-related medical visits, and 5,000 flu deaths. Hence, the increasing occurrences of seasonal influenza are steering the growth of the influenza vaccines market.

The growth of the influenza vaccines market is further expected to be propelled by the increasing aging population. This demographic trend refers to a rising proportion of elderly individuals within a society, and this population segment utilizes influenza vaccines to mitigate the heightened susceptibility to severe complications and mortality associated with influenza infections. The aging process may lead to a weakening immune system, rendering individuals more vulnerable to infectious diseases such as influenza. According to the World Health Organization (WHO) in October 2022, the global population of people aged 60 years and older is projected to double by 2050, reaching 2.1 billion. Therefore, the expanding aging population is a significant driver of the influenza vaccines market.

An emerging trend in the influenza vaccine market is the adoption of technologically advanced vaccine production methods. Companies operating in this market are embracing innovative vaccine production technologies to maintain their competitive positions. For example, in January 2023, GlaxoSmithKline PLC introduced the Multiple Antigen Presenting System (MAPS) for vaccine development, offering an innovative approach to developing effective vaccines against bacteria and viruses. This technology is particularly useful for rapid vaccine development in response to epidemic or pandemic outbreaks.

Major companies in the influenza vaccine market are focusing on advanced product innovations, such as quadrivalent seasonal influenza vaccines, to enhance their respiratory vaccine portfolios and financial standings. A quadrivalent seasonal influenza vaccine is designed to provide protection against four different flu viruses, including two influenza A viruses and two influenza B viruses. In September 2023, Clover Biopharmaceuticals Ltd. launched AdimFlu-S (QIS), a quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. The quadrivalent composition enhances the vaccine's effectiveness across different influenza B strains compared to trivalent options.

In November 2022, Pfizer Inc. entered into a partnership with BioNTech SE to develop an mRNA combination vaccine for influenza and COVID-19. This collaboration aims to initiate a phase I trial for a single-dose mRNA-based combination addressing both respiratory diseases. BioNTech SE, a Germany-based immunotherapy developer, is partnering with Pfizer Inc., a US-based pharmaceutical and biotechnology company, to advance this innovative approach to respiratory disease prevention.

Major companies operating in the influenza vaccines market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi-Aventis LLC., AstraZeneca PLC, GlaxoSmithKline plc., Serum Institute of India Private Limited, Takeda Pharmaceutical Company Limited, Moderna Inc., Viatris Inc., CSL Limited, Seqirus Inc., Daiichi Sankyo Company Limited, China National Pharmaceutical Group Corporation, Shanghai Fosun Pharmaceutical Group Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Shionogi & Co. Ltd., Liaoning Cheng Da Biotechnology Co. Ltd., Novavax AB, Sinovac Biotech Co. Ltd., Green Cross Corporation, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd., Hualan Biological Engineering Inc., Valneva SE, Bharat Biotech International Limited, Vaxess Technologies Inc., Osivax, Gamma Vaccines Pty. Ltd.

North America was the largest region in the influenza vaccines market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the influenza vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The influenza vaccines market consists of sales of recombinant influenza vaccines, high-dose influenza vaccines, cell-based influenza vaccines, and egg-based influenza vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Influenza Vaccines Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on influenza vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for influenza vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The influenza vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Vaccine Type: Inactivated; Live Attenuated
  • 2) By Valency: Quadrivalent; Trivalent
  • 3) By Route Of Administration: Injection; Nasal Spray
  • 4) By Age Group: Pediatric; Adult
  • 5) By Distribution Channel: Hospitals And Pharmacies; Government And Institutional Supply; Other Distribution Channels
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Sanofi-Aventis LLC.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Influenza Vaccines Market Characteristics

3. Influenza Vaccines Market Trends And Strategies

4. Influenza Vaccines Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Influenza Vaccines Market Size and Growth

  • 5.1. Global Influenza Vaccines Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Influenza Vaccines Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Influenza Vaccines Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Influenza Vaccines Market Segmentation

  • 6.1. Global Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Inactivated
  • Live Attenuated
  • 6.2. Global Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Quadrivalent
  • Trivalent
  • 6.3. Global Influenza Vaccines Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Injection
  • Nasal Spray
  • 6.4. Global Influenza Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Pediatric
  • Adult
  • 6.5. Global Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals And Pharmacies
  • Government And Institutional Supply
  • Other Distribution Channels

7. Influenza Vaccines Market Regional And Country Analysis

  • 7.1. Global Influenza Vaccines Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Influenza Vaccines Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Influenza Vaccines Market

  • 8.1. Asia-Pacific Influenza Vaccines Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Influenza Vaccines Market

  • 9.1. China Influenza Vaccines Market Overview
  • 9.2. China Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Influenza Vaccines Market

  • 10.1. India Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Influenza Vaccines Market

  • 11.1. Japan Influenza Vaccines Market Overview
  • 11.2. Japan Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Influenza Vaccines Market

  • 12.1. Australia Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Influenza Vaccines Market

  • 13.1. Indonesia Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Influenza Vaccines Market

  • 14.1. South Korea Influenza Vaccines Market Overview
  • 14.2. South Korea Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Influenza Vaccines Market

  • 15.1. Western Europe Influenza Vaccines Market Overview
  • 15.2. Western Europe Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Influenza Vaccines Market

  • 16.1. UK Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Influenza Vaccines Market

  • 17.1. Germany Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Influenza Vaccines Market

  • 18.1. France Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Influenza Vaccines Market

  • 19.1. Italy Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Influenza Vaccines Market

  • 20.1. Spain Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Influenza Vaccines Market

  • 21.1. Eastern Europe Influenza Vaccines Market Overview
  • 21.2. Eastern Europe Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Influenza Vaccines Market

  • 22.1. Russia Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Influenza Vaccines Market

  • 23.1. North America Influenza Vaccines Market Overview
  • 23.2. North America Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Influenza Vaccines Market

  • 24.1. USA Influenza Vaccines Market Overview
  • 24.2. USA Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Influenza Vaccines Market

  • 25.1. Canada Influenza Vaccines Market Overview
  • 25.2. Canada Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Influenza Vaccines Market

  • 26.1. South America Influenza Vaccines Market Overview
  • 26.2. South America Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Influenza Vaccines Market

  • 27.1. Brazil Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Influenza Vaccines Market

  • 28.1. Middle East Influenza Vaccines Market Overview
  • 28.2. Middle East Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Influenza Vaccines Market

  • 29.1. Africa Influenza Vaccines Market Overview
  • 29.2. Africa Influenza Vaccines Market, Segmentation By Vaccine Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Influenza Vaccines Market, Segmentation By Valency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Influenza Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Influenza Vaccines Market Competitive Landscape And Company Profiles

  • 30.1. Influenza Vaccines Market Competitive Landscape
  • 30.2. Influenza Vaccines Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann-La Roche Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Novartis AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Sanofi-Aventis LLC.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Influenza Vaccines Market Other Major And Innovative Companies

  • 31.1. AstraZeneca PLC
  • 31.2. GlaxoSmithKline plc.
  • 31.3. Serum Institute of India Private Limited
  • 31.4. Takeda Pharmaceutical Company Limited
  • 31.5. Moderna Inc.
  • 31.6. Viatris Inc.
  • 31.7. CSL Limited
  • 31.8. Seqirus Inc.
  • 31.9. Daiichi Sankyo Company Limited
  • 31.10. China National Pharmaceutical Group Corporation
  • 31.11. Shanghai Fosun Pharmaceutical Group Co. Ltd.
  • 31.12. Mitsubishi Tanabe Pharma Corporation
  • 31.13. Shionogi & Co. Ltd.
  • 31.14. Liaoning Cheng Da Biotechnology Co. Ltd.
  • 31.15. Novavax AB

32. Global Influenza Vaccines Market Competitive Benchmarking

33. Global Influenza Vaccines Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Influenza Vaccines Market

35. Influenza Vaccines Market Future Outlook and Potential Analysis

  • 35.1 Influenza Vaccines Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Influenza Vaccines Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Influenza Vaccines Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer